Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Blunt Injury
Interventions: Open repair of thoracic aorta injury, TEVAR; Procedure
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: COPD
Interventions: Bipap (Respironics, Inc); Device
Lead sponsor: University of Iowa; Other
Eligibility: 35 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Extramammary Paget's Disease, Extramammary Paget Disease, Paget Disease, Extramammary, Extramammary Paget's Disease of Vulva (Diagnosis), Extramammary Paget's Disease of Vagina (Diagnosis), Extramammary Paget's Disease Vulva Invasive, Extramammary Paget's Disease of Anus (Diagnosis), Extramammary Paget's Disease of Anal Canal (Diagnosis), Extramammary Paget's Disease of Skin
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2050
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: ICU Acquired Weakness
Interventions: TetraGraph, Electromyography, Nerve conduction studies; Device
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Heart Failure, Congestive
Interventions: BioZ Dx; Device
Lead sponsor: CardioDynamics; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Sacramento, California • San Diego, California

Conditions: Candidiasis
Interventions: micafungin, amphotericin B deoxycholate; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 48 Hours to 120 Days
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Orange, California • New Brunswick, New Jersey • Durham, North Carolina + 2 more

Conditions: Stroke
Interventions: Portable Neuromodulation Stimulation, Sham, Gait and balance training; Device · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 22 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Baseline, Hemodilution
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Squamous Cell Carcinoma
Interventions: Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream, Nourivan Base Cream; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Intra-amniotic Infection
Interventions: Not listed
Lead sponsor: ProteoGenix, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 21
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 16 more

Conditions: Fat Necrosis, Muscle Stimulation
Interventions: Accufit; Device
Lead sponsor: CynosureLutronic; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Billerica, Massachusetts • New York, New York

Conditions: Pain, Postoperative
Interventions: ropivacaine; Drug
Lead sponsor: Liberman, Eric, D.O.; Individual
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Livingston, New Jersey

Conditions: HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer, Stage IA Breast Cancer
Interventions: Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Toremifene Citrate; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 60 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Endometrial Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 55 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Communication
Interventions: Dolores One; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions: Onvansertib, Paclitaxel; Drug
Lead sponsor: Antonio Giordano, MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Stroke
Interventions: Surface functional electrical stimulation (FES), Motor learning, Brain computer interface (BCI) training; Other
Lead sponsor: Louis Stokes VA Medical Center; Federal
Eligibility: 22 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Invasive Ductal and Invasive Lobular Breast Carcinoma, Stage 0 Breast Carcinoma, Stage I Breast Carcinoma, Stage II Breast Carcinoma
Interventions: Intraoperative Radiotherapy; Procedure
Lead sponsor: St. Joseph Hospital of Orange; Other
Eligibility: 41 Years to 90 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Orange, California

Conditions: Stroke, Mild Cognitive Impairment
Interventions: Transcranial Dirrect Current Stimulation; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Distal Urethral Cancer, Proximal Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage II Bladder Cancer, Stage III Bladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: gemcitabine hydrochloride, cisplatin, therapeutic conventional surgery, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiac Resynchronization Therapy, Chronic Heart Failure, Left Bundle-Branch Block
Interventions: CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment; Device
Lead sponsor: XSpline S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: Intermittent Theta Burst Stimulation (iTBS), Transcranial Alternating Current Stimulation (tACS), Psychotherapy, Sham (Placebo) Transcranial Alternating Current Stimulation (tACS); Device · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: fulvestrant, anastrozole; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 856
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more

Conditions: Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Eribulin Mesylate, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 39
States / cities: Scottsdale, Arizona • Newark, Delaware • Washington D.C., District of Columbia + 33 more

Search by objective public record fields.

Thoracic Endovascular Repair Versus Open Surgery for Blunt Injury

Trial of Non-invasive Ventilation for Stable COPD

Gynecologic Extramammary Paget's Disease

ICU CONNECT: Study Comparing EMG in Healthy Volunteers and ICU Patients.

PREVENT-HF: Prevention of Heart Failure Events With Impedance Cardiography Testing

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

Neuromodulation and Dynamic Balance in Stroke

Performance of Non-Invasive Monitors During ANH

Combination 5-FU / Calcipotriene Cream for SCCIS/SCC

Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes

Safety and Efficacy of Electronic Stimulation for Circumferential Reduction and Muscle Toning

Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

Dolores One: Maximizing Functional Communication for Adults

Onvansertib + Paclitaxel In TNBC

Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke

Single Fraction Intraoperative Radiotherapy

tDCS for Post-Stroke Cognitive Impairment

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

CARED : A Novel Rapid Treatment Paradigm for Depression

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer